Drug company Natco Pharma said on Monday that it has received the emergency use of Baricitinib tablets in India to treat COVID-19 positive patients. According to the company, it has been approved by the Central Drugs Standard Control Organization (CDSCO) in India. CDSCO is responsible for approving drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs in the country, and coordinating the work of the State Drug Control Organization.
CDSCO granted permission
The company said in a regulatory filing that Natco Pharma Ltd has received approval for use in emergency use. The company said that 1mg, 2mg and 4mg of Baricitinib tablets have been approved by the Central Drugs Standard Control Organization (CDSCO) in India. According to the company, Baricitinib is used in the treatment of COVID-19 positive patients with Remdesivir.
Natco said it would request a mandatory license based on emergency usage and in view of the severe and severe public health emergency caused by the epidemic across India. He further said that the company is ready to launch the product this week, so that it can be made available to the patients suffering all over the country. Natco Pharma shares were trading at Rs 926.70 per share on the BSE, up 3.35 per cent.
Covid-19 Vaccine: Pfizer vaccine is expected to be approved in India soon, company said, talks with Government of India
At the same time, Pfizer, one of the first companies in the world to manufacture Corona vaccine, has said that its vaccine in India is expected to be approved soon. The American company has informed that it is talking to the Indian government to get its vaccine approved as soon as possible. The company has also announced today that it is sending medicines worth over $ 70 million, or Rs 510 crore, on its behalf, to help it control the Corona explosion in India.